- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00161876
FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years
May 20, 2015 updated by: Pfizer
Open-label, Multicenter, Follow-up Phase III Study to Investigate the Safety of the Third Vaccination of FSME-IMMUN NEW in Volunteers Aged 16 to 66 Years
The aim of this study is to evaluate the safety of the third vaccination with FSME-IMMUN NEW in all volunteers who received both vaccinations in Baxter study 208 (safety study of FSME IMMUN NEW and ENCEPUR in healthy volunteers aged 16 to 65 years).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
3973
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Debica, Poland, 33-200
- Zespol Opieki Zdrowotnej w Debicy
-
Kielce, Poland, 25-381
- Wojewodzki Szpital Dzieciecy Oddzial Obserwacyjno - Zakazny A
-
Krakow, Poland, 31-202
- Szpital Jana Pawla II Oddzial Neuroinfekcji
-
Krakow, Poland, 30-018
- "Atopia" Diagnostyka i Leczenie Chorob Alergicznych i Ukladu Oddechowego
-
Krakow, Poland, 30-969
- Przedsiebiorstwo Uslug Medycznych "Centrum Medyczne Nowa Huta"
-
Lubartow, Poland, 21-100
- Samodzielny Publiczny Zaklad Opieki Zdrowotnej Oddzial Pediatryczny
-
Olsztyn, Poland, 10-461
- PANTAMED sp. z o.o.
-
Tarnow, Poland, 33-100
- Oddzial Chorób Zakaznych Specjalistyczny Szpital im. E. Szczeklika
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 66 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Received two vaccinations during the course of Baxter study 208
- Understand the nature of the study, agree to its provisions and give written informed consent
- For volunteers under 18 years of age - written informed consent of the parents/legal guardian is given
Exclusion Criteria:
- None.
Volunteers assessed for eligibility to receive a third vaccination.
Eligibility to receive third vaccination:
- ELISA value > 126 VIE U/ml before the first TBE vaccination in Baxter study 208
- Not clinically healthy, (i.e. the physician would have reservations vaccinating with FSME-IMMUN NEW outside the scope of a clinical trial)
- Have already been administered a third TBE vaccination elsewhere since receiving the two vaccinations in Baxter study 208
- Have had an allergic reaction to one of the components of the vaccine since the last vaccination in Baxter study 208
- Suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids, chemotherapeutics) that can be expected to influence immunological functions
- Have a known or suspected problem with drug or alcohol abuse (> 4 liters wine / week or equivalent dose of other alcoholic beverages)
- Have received banked human blood or immunoglobulins within one month of study entry
- Are known to have become infected with HIV (a special HIV test is not required for the purpose of the study) since the last visit of study 208
- Have had a vaccination against yellow fever and / or Japanese B-encephalitis since the last visit in study 208
- Have received an investigational new drug within 6 weeks prior to study start
- Have a positive pregnancy test at the first medical examination (for females capable of bearing children)
- Do not agree to employ adequate birth control measures for the duration of the study (for females capable of bearing children)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jerzy Romaszko, MD, PANTAMED sp. z o o.
- Principal Investigator: Jerzy Brzostek, MD, Zespol Opieki Zdrowotnej w Debicy
- Principal Investigator: Jerzy Dziduch, MD, Samodzielny Publiczny Zaklad Opieki Zdrowotnej Oddzial Pediatryczny
- Principal Investigator: Marian Patrzalek, MD, Wojewodzki Szpital Dzieciecy Oddzial Obserwacyjno - Zakazny A
- Principal Investigator: Krzysztof Sladek, MD, "Atopia" Diagnostyka i Leczenie Chorob Alergicznych i Ukladu Oddechowego
- Principal Investigator: Krystyna Jurowska, MD, Przedsiebiorstwo Uslug Medycznych "Centrum Medyczne Nowa Huta"
- Principal Investigator: Ryszard Konior, Szpital Jana Pawla II Oddzial Neuoinfekcji
- Principal Investigator: Grazyna Zawada-Skrobisz, MD, Oddzial Chorob Zakaznych Specjalistyczny Szpital, Tarnow
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2002
Study Completion
August 1, 2002
Study Registration Dates
First Submitted
September 8, 2005
First Submitted That Met QC Criteria
September 12, 2005
First Posted (Estimate)
September 13, 2005
Study Record Updates
Last Update Posted (Estimate)
May 21, 2015
Last Update Submitted That Met QC Criteria
May 20, 2015
Last Verified
May 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Encephalitis, Arbovirus
- Encephalitis, Viral
- Central Nervous System Viral Diseases
- Central Nervous System Infections
- Infectious Encephalitis
- Arbovirus Infections
- Vector Borne Diseases
- Flavivirus Infections
- Flaviviridae Infections
- Tick-Borne Diseases
- Encephalitis
- Encephalitis, Tick-Borne
Other Study ID Numbers
- 213
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Encephalitis, Tick-borne
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)TerminatedTick-Borne Disease | Encephalitis, Tick-Borne | Tick-Borne Encephalitis | Glycoprotein E, Flavivirus | NSI Protein, FlavivirusUnited States
-
Medical University of ViennaAustrian Science Fund (FWF)CompletedTick Borne EncephalitisAustria
-
PfizerCompletedTick-borne Encephalitis (TBE)Poland
-
Sykehuset TelemarkNorwegian Institute of Public Health; Oslo University Hospital; Sorlandet Hospital... and other collaboratorsRecruiting
-
PfizerCompleted
-
GlaxoSmithKlineNovartis VaccinesCompleted
-
Novartis VaccinesCompleted
-
National Institute of Allergy and Infectious Diseases...Johns Hopkins Bloomberg School of Public HealthCompletedTick-Borne EncephalitisUnited States
-
University Medical Centre LjubljanaUniversity of Ljubljana School of Medicine, SloveniaRecruiting
-
University of SurreyCompletedTick-Borne EncephalitisUnited Kingdom
Clinical Trials on Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
-
PfizerCompletedEncephalitis, Tick-borneBelgium
-
PfizerCompletedEncephalitis, Tick-borneAustria, Germany
-
PfizerCompletedEncephalitis, Tick-borneAustria
-
PfizerCompletedEncephalitis, Tick-bornePoland
-
PfizerCompletedEncephalitis, Tick-BorneGermany, Austria, Poland
-
PfizerCompletedEncephalitis, Tick-borneGermany
-
PfizerCompletedEncephalitis, Tick-BornePoland
-
PfizerCompletedEncephalitis, Tick-BorneAustria, Czechia
-
NovartisNovartis VaccinesCompletedEncephalitis, Tick-BorneGermany
-
PfizerCompletedTick-borne EncephalitisAustria, Germany